Studies are already underway
New Omicron vaccine expected by September
5/5/2022, 8:13 p.m
The Omikron vaccine should be on the market by the end of September at the latest. As announced by the European Medicines Agency, the necessary studies are already underway. In particular, the focus would be on adapting existing vaccines from Moderna and Biontech.
According to the European Medicines Agency (EMA), vaccines once morest the highly contagious omicron variant of the coronavirus might be approved by the end of September at the latest. The greatest opportunities are for appropriately adapted mRNA vaccines from the companies Moderna and Biontech, said EMA Director for Vaccination Strategy Marco Cavaleri. The necessary clinical studies are in progress.
The EMA also examines preparations from other manufacturers. However, it is “no secret” that the adaptations of mRNA vaccines from Moderna and Biontech to Omikron are already quite advanced. He did not give details of the study data collected so far.
At the same time, Cavaleri appealed to unvaccinated people to protect themselves once morest corona by vaccination before autumn and winter. “The top priority must be closing the vaccination gap.” Only 50 percent of Europeans have been fully vaccinated and boosted to date, while 15 percent of Europeans over the age of 18 have not yet received a single vaccination once morest Covid-19.
